

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496
	APPLICANT Sudhir V. Shah	
	FILING DATE	CONFIRMATION NO.
		GROUP 1654

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
W	AA	5,047,421	Sep 10, 1991	Green
W	AB	5,721,209	Feb 24, 1998	Horwitz <i>et al.</i>
W	AC	5,811,127	Sep 22, 1998	Milstein <i>et al.</i>
W	AD	4,684,482	Aug 4, 1987	Green
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER <i>Kelleher</i>	DATE CONSIDERED 01/26/04
-----------------------------	-----------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496
		APPLICANT Sudhir V. Shah	
		FILING DATE	CONFIRMATION NO.
			GROUP 1654

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
N	AL	WO 94/01770 A	20 Jan 94	PCT	X
N	AM	DE 40 08 323 A	19 Sept 91	Germany	X
N	AN	WO 00 13706 A	16 Mar 00	PCT (English)	
N	AO	WO 91 07956 A	13 June 91	PCT	
	AP				
	AQ				
	AL2				
	AM2				
	AN2				
	AO2				
	AP2				
	AQ2				
	AL3				
	AM3				
	AN3				
	AO3				
	AP3				
	AQ3				
	AL4				
	AM4				
	AN4				
	AO4				
	AP4				
	AQ4				
	AL5				
	AM5				

EXAMINER <i>Halelur</i>	DATE CONSIDERED <i>04/26/04</i>
----------------------------	------------------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496
		APPLICANT Sudhir V. Shah	
		FILING DATE	CONFIRMATION NO.
			GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AR	Sumboonnanonda, A., et al., "Renal tubular function in β-thalassemia", <i>Pediatr Nephrol</i> , 12:280-283.		
AS	Ong-ajyooth, L., et al., "Renal Function in Adult Beta-Thalassemia/Hb E Disease", <i>Nephron</i> , 78:156-161 (1998).		
AT	Guasch, A., et al., "Evidence that Microdeletions in the α Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans", <i>J Am Soc Nephrol</i> , 10:1014-1019 (1999).		
AU	Loebstein, R., et al., "Diabetic Nephropathy in Hypertransfused Patients with β-Thalassemia", <i>Diabetes Care</i> , 21(8):1306-1309 (1998).		
AV	Ongajyooth, L., et al., "Glomerulonephritis in β-thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", <i>J Med Assoc Thai</i> , 78(3):119-126 (1995).		
AW	Aoki, R.Y., et al., "Microalbuminuria in Sickle Cell Disease", <i>Brazilian J Med Biol Res</i> , 23:1103-1106 (1990).		
AX	Katopodis, K.P., et al., "Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia", <i>Journal of Nephrology</i> , 10(3):163-167 (1997).		
AY	Pham, P.-T.T., et al., "Renal abnormalities in sickle cell disease", <i>Kidney International</i> , 57:1-8 (2000).		
AZ	Kontoghiorghes, G.J., et al., "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", <i>Inorganica Chimica Acta</i> , 136:L11-L12 (1987).		
AR2	Falk, R.J., et al., "Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Converting Enzyme", <i>The New England Journal of Medicine</i> , 326(14):910-915 (1992).		
AS2	Guasch, A., et al., "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", <i>Kidney International</i> , 51:826-833 (1997).		
AT2	Cianciulli, P., et al., "Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy", <i>Kidney International</i> , 46:467-470 (1994).		
AU2	Ueda, N., et al., "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", <i>Kidney International</i> , 49:370-373 (1996).		

EXAMINER 	DATE CONSIDERED 24/11/04
---	-----------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496
		APPLICANT Sudhir V. Shah	
		FILING DATE	CONFIRMATION NO.
			GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
✓ AV2	Savill, J., et al., "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2 nd ed., pages 404-439, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).		
✓ AW2	Ueda, N., et al., "In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", <i>Kidney: A Current Survey of World Literature</i> , 6:143-146 (1997).		
✓ AX2	Boyce, N.W., et al., "Hydroxyl radical mediation of immune renal injury by desferrioxamine", <i>Kidney International</i> , 30:813-817 (1986).		
✓ AY2	Baliga, R., et al., "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", <i>J Am Soc Nephrol</i> , 7(8):1183-1188 (1996).		
✓ AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", <i>The American Physiological Society</i> , F337-F344(1988).		
✓ AR3	Thakur, V., et al., "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", <i>Kidney International</i> , 34:494-499 (1988).		
✓ AS3	Nankivell, B.J., et al., "The Role of Tubular Iron Accumulation in the Remnant Kidney", <i>J Am Soc Nephrol</i> , 4(8):1598-1607 (1994).		
✓ AT3	Alfrey, A.C., et al., "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", <i>Kidney International</i> , 36:753-759 (1989).		
✓ AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2 nd ed., pages 1749-1788, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).		
✓ AV3	Howard R.L., et al., "Urinary albumin, transferrin and iron excretion in diabetic patients", <i>International Society of Nephrology</i> , 40:923-926 (1991).		
✓ AW3	Olivieri, N.F., et al., "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", <i>The New England Journal of Medicine</i> , 918-922 (1995).		
✓ AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", <i>American Journal of Physiology</i> , 263(4):F637-F641 (1992).		
✓ AY3	Wu,Z-L, et al., "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," <i>Renal Failure</i> 16(4):471-480 (1994).		

EXAMINER 	DATE CONSIDERED 04/26/04
---	-----------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2629.1003-010	DIVISIONAL APPLICATION NO. 09/553,496	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION November 14, 2003 (Use several sheets if necessary)	APPLICANT Sudhir V. Shah		
	FILING DATE	CONFIRMATION NO.	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <i>Reeler</i>	DATE CONSIDERED 04/26/64
---------------------------	-----------------------------